1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sanofi India Limited

Sanofi India Limited

2,775.40
INR
-56.35
(-1.99%)
137.78EPS
24.73P/E
78.47BMarket Cap
Oct 29Next Earn
Sanofi India Limited
BSE:SANOFI
(Bombay Stock Exchange)

Recent

price

2,775.40

P/E

ratio

24.73

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
INR
471.09
559.85
679.01
780.34
851.23
943.14
1,037.23
1,070.88
1,189.59
1,307.09
1,245.3
1,269.31
1,184.16
860.42
863.63
791.73
753.86
Revenue per Share
67.31
83.01
76.71
115.14
114.46
139.6
132.09
141.55
165.26
179.85
207.38
410.06
269.47
261.78
179.54
141.85
137.78
Basic EPS, GAAP
42.24
60.49
125.82
118.34
115.04
92.57
139.86
164.17
136.64
146.11
247.37
232.65
163.48
85.15
184.67
179.15
- -
Free Cash Flow per Basic Share
23.9
63.92
38.35
45.4
52.65
63.65
65
68.04
71.04
66
349.01
364.99
683
377.02
167
192.01
- -
Dividend per Share
440.35
484.84
522.83
584.74
645.16
763.55
817.61
879.87
963.59
1,060.46
920.08
966.37
553.96
440.8
373.68
325.31
358.65
Book Value per Share
436.81
236.5
289.58
367.42
443.85
622.91
702.37
780.61
881.26
995.02
871.8
964.11
551.74
437.55
373.11
325
358.35
Tangible Book Value per Share
23
23
23
23
23
23
23
23
23
23
23
23
23
23
23
23
23
Basic Weighted Avg Shares
10,850
12,894
15,638
17,972
19,604
21,721
23,888
24,663
27,397
30,103
28,680
29,233
27,272
19,816
19,890
18,234
17,361
Sales/Revenue/Turnover
21.76
16.82
14.2
17.37
12.62
16.01
17.43
17.69
19.08
18.85
22.1
23.8
24.41
22.88
22.81
24.9
23.43
Operating Margin (%)
197
312
899
923
966
1,130
1,188
1,022
1,027
999
822
667
419
396
382
373
365
Depreciation Expense
1,550
1,912
1,767
2,652
2,636
3,215
3,042
3,260
3,806
4,142
4,776
9,444
6,206
6,029
4,135
3,267
3,173
Net Income, GAAP
31.74
32.68
32.5
33.95
35.62
40.14
36.68
36.65
37.59
30.96
29.47
24.9
28.2
31.01
27.28
26.53
25.74
Effective Tax Rate (%)
14.29
14.83
11.3
14.76
13.45
14.8
12.73
13.22
13.89
13.76
16.65
32.31
22.76
30.42
20.79
17.92
18.28
Profit Margin (%)
8,196
3,098
4,420
4,782
6,070
7,560
10,732
8,421
9,687
14,259
11,465
13,883
8,697
5,967
3,903
3,092
3,949
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
179
176
149
139
140
137
108
LT Debt
10,142
11,166
12,041
13,467
14,858
17,585
18,830
20,264
22,192
24,423
21,190
22,256
12,758
10,152
8,606
7,492
8,260
Total Equity
16.56
13.72
12.93
16.18
11.32
12.62
14.17
13.85
15.04
14.7
17.27
37.49
29.03
23.97
26.33
31.12
- -
Return on Invested Capital (%)
16.13
17.97
15.31
20.81
18.63
19.83
16.79
16.71
17.95
17.78
20.89
43.07
35.04
51.77
43.32
39.83
- -
Return on Capital (%)
15.93
17.94
15.22
20.79
18.61
19.82
16.71
16.68
17.93
17.77
20.94
43.47
35.45
52.63
44.09
40.59
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
41
- -
39
LT Borrowings
- -
- -
- -
LT Finance Leases
137
- -
108
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
94,234
73,859
78,465

Working Capital

INR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
8,006
- -
9,650
Cash, Cash Equivalents & STI
2,777
- -
3,740
Accounts Receivable, Net
1,767
- -
2,321
Inventories
3,116
- -
3,112
Total Current Liabilities
4,914
- -
5,701
Payables & Accruals
- -
- -
- -
ST Debt
41
- -
39
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-6.52%
-17.25%
-12.94%
Free Cash Flow
15.82%
6.06%
-2.99%
Net Income, GAAP
5.09%
1.64%
-20.99%
Sales/Revenue/Turnover
-1.06%
-8.02%
-8.33%
Total Cash Common Dividend
43.91%
1.24%
14.98%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,108
4,635
5,240
5,149
19,890
2025
5,359
4,063
- -
4,198
18,234
2026
4,723
4,377
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
59.31
44.9
35.69
39.64
179.54
2025
51.89
30.18
- -
26.79
141.85
2026
44.55
36.26
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
167
2025
- -
- -
- -
- -
192.01
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sanofi India Limited, a leading multinational pharmaceutical company in India (NSE: SANOFI), manufactures and markets a broad portfolio of branded prescription medicines and vaccines across key therapeutic areas including diabetes, cardiology, thrombosis, thromboprophylaxis, central nervous system disorders, anti-infectives, pain management, anti-histamines, rare diseases, and transplant needs; notable brands encompass Lantus and Soliqua for diabetes, Combiflam for pain relief, Allegra for allergies, Amaryl for glycemic control, Insuman insulin products, Lasix for diuresis, Menactra vaccine, Stilnoct for insomnia, and various formulations such as tablets, capsules, eye/ear drops, ampoules, vials, creams, and ointments. Incorporated in May 1956 as Hoechst Fedco Pharma Private Limited in Mumbai, where it maintains headquarters at Sanofi House in Powai, the company operates two primary manufacturing facilities in Hyderabad and Goa adhering to global quality standards approved by regulators including MHRA (UK), TGA (Australia), and ANVISA (Brazil), supplemented by third-party manufacturing for domestic distribution and exports to Russia, Ukraine, and other CIS countries. Sanofi, the world's leading healthcare company, and its wholly-owned subsidiary Hoechst GmbH collectively hold 60.4% of its equity, with the remainder publicly listed. In recent strategic developments, Sanofi India has strengthened its market presence through partnerships with Indian firms including Cipla, Dr. Reddy's Laboratories, and Emcure Pharmaceuticals to enhance distribution of legacy brands and vaccines; it continues to launch innovative products such as the AllStar insulin pen and Combiflam Plus while outlining growth plans in diabetes and consumer healthcare segments, bolstered by robust manufacturing collaborations with 15 contract organizations. The company employs over 3,000 people across India and focuses on sustainable growth amid a competitive pharmaceutical landscape.